Promoter prognostication: The serotonin transporter gene and antidepressant response

Molecular Psychiatry

Volumn 3, Issue 6, 1998, Pages 475-476

  Kelsoe, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PINDOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ALLELE; DEPRESSION; DNA POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR CLONING; MOOD; PRIORITY JOURNAL; PROMOTER REGION; SEROTONINERGIC SYSTEM; SHORT SURVEY;

EID: 0031795517     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000461     Document Type: Short Survey

References (12)

1. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Pétri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531.
2. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin 'transporter'. Arch Gen Psychiatry 1981; 38: 1315-1317.
3. Suranyi-Cadotte BE, Quirion R, Nair NP, Lafaille F, Schvvartz G. Imipramine treatment differentially affects platelet 3H- imipramine binding and serotonin uptake in depressed patients. Life Sci 1985; 36: 795-799.
4. Lawrence KM, Katona CL, Abou-Saleh MT, Robertson MM, Nairac BL, Edwards DR et al. Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine. Psychopharmacology (Berl) 199"47 115: 261-264.
5. Gronier B, Azorin JM, Dassa D, Jeanningros R. Lack of association between platelet tritiated imipramine binding and clinical status of depressed patients on chronic antidepressant treatment. Eur Neuropsychopharmacol 1994; 4: 7-14.
6. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D e( al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1996; 1: 453-460.
7. Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES et al. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 1998; 81: 58-63.
8. Battersby S, Ogilvie AD, Smith CA, Blackwood DH, Muir WJ, Quinn JP et al. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet 1996; G: 177-181.
9. Stahl S. 5HT1A receptors and pharmacotherapy. Is serotonin receptor downregulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994; 30: 39-13.
10. Romero L, Bel N, Artigas F, de Montigny C, Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996; 15: 349-360.
11. Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry 1995; 52: 969-971.
12. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154: 37-43.